BUZZ-肺病药物未能达到试验目标，Tvardi Therapeutics跌停

路透中文

Yesterday

BUZZ-肺病药物未能达到试验目标，Tvardi <a href="https://laohu8.com/S/LENZ">Therapeutics</a>跌停

10月13日 - ** 药物开发商Tvardi Therapeutics TVRD.O股价盘前下跌88.6%至4.73美元

** 公司称其试验性药物TTI-101在特发性肺纤维化（一种慢性进行性肺病）患者的中期试验中未能达到预期目标

** 该试验对 88 名患者进行了 TTI-101 作为独立疗法或与德国勃林格殷格翰公司的宁替尼（nintedanib）联合疗法的评估

** Nintedanib已获得FDA批准，用于减缓IPF和其他肺部疾病患者的肺功能衰退。

** 试验中治疗组的停药率很高，400 毫克剂量为 56.7%，800 毫克剂量为 62.1%，而安慰剂的停药率为 10.3

** 大多数停药是由于胃肠道副作用，尤其是同时接受宁替达尼治疗的患者--TVRD

** 公司补充说，早期结果显示，该药对肺功能的改善与安慰剂相似

** 截至上一交易日收盘，该公司股价已上涨一倍多

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2575405106"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575405106\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575405106?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-10-13 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575405106","market":"us","top_or_hot":-1,"title":"BUZZ-肺病药物未能达到试验目标，Tvardi Therapeutics跌停","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-肺病药物未能达到试验目标，Tvardi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>跌停</title></head><body><p><span>10月13日</span><span> - </span>** 药物开发商Tvardi Therapeutics <span>TVRD.O</span>股价盘前下跌88.6%至4.73美元</p><p>** 公司称其试验性药物TTI-101在特发性肺纤维化（一种慢性进行性肺病）患者的中期试验中未能达到预期目标</p><p>** 该试验对 88 名患者进行了 TTI-101 作为独立疗法或与德国勃林格殷格翰公司的宁替尼（nintedanib）联合疗法的评估</p><p>** Nintedanib已获得FDA批准，用于减缓IPF和其他肺部疾病患者的肺功能衰退。</p><p>** 试验中治疗组的停药率很高，400 毫克剂量为 56.7%，800 毫克剂量为 62.1%，而安慰剂的停药率为 10.3</p><p>** 大多数停药是由于胃肠道副作用，尤其是同时接受宁替达尼治疗的患者--TVRD</p><p>** 公司补充说，早期结果显示，该药对肺功能的改善与安慰剂相似</p><p>** 截至上一交易日收盘，该公司股价已上涨一倍多</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-肺病药物未能达到试验目标，Tvardi Therapeutics跌停</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-肺病药物未能达到试验目标，Tvardi Therapeutics跌停\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-10-13 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-肺病药物未能达到试验目标，Tvardi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>跌停</title></head><body><p><span>10月13日</span><span> - </span>** 药物开发商Tvardi Therapeutics <span>TVRD.O</span>股价盘前下跌88.6%至4.73美元</p><p>** 公司称其试验性药物TTI-101在特发性肺纤维化（一种慢性进行性肺病）患者的中期试验中未能达到预期目标</p><p>** 该试验对 88 名患者进行了 TTI-101 作为独立疗法或与德国勃林格殷格翰公司的宁替尼（nintedanib）联合疗法的评估</p><p>** Nintedanib已获得FDA批准，用于减缓IPF和其他肺部疾病患者的肺功能衰退。</p><p>** 试验中治疗组的停药率很高，400 毫克剂量为 56.7%，800 毫克剂量为 62.1%，而安慰剂的停药率为 10.3</p><p>** 大多数停药是由于胃肠道副作用，尤其是同时接受宁替达尼治疗的患者--TVRD</p><p>** 公司补充说，早期结果显示，该药对肺功能的改善与安慰剂相似</p><p>** 截至上一交易日收盘，该公司股价已上涨一倍多</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVRD","symbol_name":"Tvardi Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nL3T3VU0RU:1","article_id":"2575405106","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575405106","pubTimestamp":1760356979,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"TVRD":"Tvardi Therapeutics Inc","BK4007":"制药"},"translate_title":"BUZZ-Lung disease drug fails to meet trial target, Tvardi Therapeutics hits limit","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVRD":0.9},"content_text":"BUZZ-肺病药物未能达到试验目标，Tvardi Therapeutics跌停10月13日 - ** 药物开发商Tvardi Therapeutics TVRD.O股价盘前下跌88.6%至4.73美元** 公司称其试验性药物TTI-101在特发性肺纤维化（一种慢性进行性肺病）患者的中期试验中未能达到预期目标** 该试验对 88 名患者进行了 TTI-101 作为独立疗法或与德国勃林格殷格翰公司的宁替尼（nintedanib）联合疗法的评估** Nintedanib已获得FDA批准，用于减缓IPF和其他肺部疾病患者的肺功能衰退。** 试验中治疗组的停药率很高，400 毫克剂量为 56.7%，800 毫克剂量为 62.1%，而安慰剂的停药率为 10.3** 大多数停药是由于胃肠道副作用，尤其是同时接受宁替达尼治疗的患者--TVRD** 公司补充说，早期结果显示，该药对肺功能的改善与安慰剂相似** 截至上一交易日收盘，该公司股价已上涨一倍多(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}